British Journal of Pharmacology
September 1, 1999
D T Malone, D A Taylor
1. The present study was undertaken to investigate the effect of Delta9-tetrahydrocannabinol (Delta9-THC) and possible serotoninergic involvement on the extracellular level of dopamine (DA) in the striatum using microdialysis in conscious, freely-moving rats. 2. A dose-dependent increase in striatal DA release occurred after i.v. administration of 0.5 - 5 mg kg-1 Delta9-THC when compared with...
European Journal of Neuroscience
September 1, 1999
Viktor L. Arvanov, Xiaofu Liang, Angelo Russo et al.
64 citations
Abstract Both the phenethylamine hallucinogen (–)‐1‐2,5‐dimethoxy‐4‐bromophenyl‐2‐aminopropane (DOB), a selective serotonin 5‐HT 2A,2C receptor agonist, and the indoleamine hallucinogen d ‐lysergic acid diethylamide (LSD, which binds to 5‐HT1A, 1B, 1D, 1E, 1F, 2A, 2C, 5, 6, 7, dopamine D 1 and D 2 , and α 1 and α 2 adrenergic receptors), but not their non‐hallucinogenic congeners, inhibited...
Progress in Neurobiology
July 1999
A Ameri
Cannabinoids have a long history of consumption for recreational and medical reasons. The primary active constituent of the hemp plant Cannabis sativa is delta9-tetrahydrocannabinol (delta9-THC). In humans, psychoactive cannabinoids produce euphoria, enhancement of sensory perception, tachycardia, antinociception, difficulties in concentration and impairment of memory. The cognitive...
Neuropsychopharmacology
July 1, 1999
J Väisänen, A M Lindén, M Lakso et al.
We have characterized excitatory effects of non-competitive NMDA receptor antagonists MK-801, PCP, and ketamine in the rat entorhinal cortex and in cultured primary entorhinal cortical neurons using expression of immediate early gene c-fos as an indicator. NMDA receptor antagonists produced a strong and dose-dependent increase in c-fos mRNA and protein expression confined to neurons in the...
Pharmacology, Biochemistry, and Behavior
July 1, 1999
Karen K. Szumlinski, Isabelle M Maisonneuve, Stanley D Glick
14 citations
Pretreatment (19 h) with the putative antiaddictive agent, ibogaine, has been shown previously to potentiate cocaine-induced locomotion in rats. The present study demonstrates that the magnitude of this effect of ibogaine is dependent on the previous cocaine history of the animal, on the time following ibogaine treatment, and on the number of ibogaine treatments. Compared to rats with no...
Psychopharmacology
July 1, 1999
Karen K. Szumlinski, Isabelle M Maisonneuve, Stanley D Glick
14 citations
Results of single-dose studies suggest that the effects of pretreatment with the putative anti-addictive compound, ibogaine, on drug-induced locomotor behavior depends on the previous drug history of the animal. To compare the effects of ibogaine pretreatment on the dose-locomotor response function for cocaine in rats treated chronically with either saline or cocaine. Rats were chronically...
Liver
June 1, 1999
G. Beitia, A. Cobreros, L. Sainz et al.
Abstract:Aims/Background: Hepatocellular damage has been reported as a consequence of 3,4‐methylenedioxymethamphetamine (MDMA) intake. However, little is known about the cellular mechanisms involved. The present study was undertaken to evaluate the effects of MDMA on cell viability as well as free calcium levels ([Ca2+]i) in short‐term cultured hepatocytes. Reduced glutathione (GSH),...
Trends in Neurosciences
June 1999
E Perry, M Walker, J Grace et al.
The cholinergic system is one of the most important modulatory neurotransmitter systems in the brain and controls activities that depend on selective attention, which are an essential component of conscious awareness. Psychopharmacological and pathological evidence supports the concept of a 'cholinergic component' of conscious awareness. Drugs that antagonize muscarinic receptors induce...
Pharmacology & Toxicology
June 1, 1999
María Isabel Colado, Raquel Ena María Granados, Esther O’shea et al.
26 citations
Abstract: Administration of a single dose of the recreationally used drug 3, 4‐methylenedioxyethamphetamine (MDEA or “eve”) to Dark Agouti rats resulted in an acute dose‐dependent hyperthermic response. The peak effect and duration of hyperthermia of a dose of MDEA of 35 mg/kg intraperitoneally was similar to a dose of 3, 4‐methylenedioxymetham‐phetamine (MDMA or “ecstasy”) of 15 mg/kg...
Pharmacology & Toxicology
May 1, 1999
C Johansson, A M Deveney, D Reif et al.
We have previously shown that the non-specific nitric oxide synthase inhibitor L-NAME blocks the behavioural effects of phencyclidine, but not d-amphetamine. To characterise the specificity of these effects, we used the specific neuronal nitric oxide synthase inhibitor AR-R 17477 in two rat models of psychosis: the prepulse inhibition of the acoustic startle response and locomotor activity. In...